Glucocorticoid metabolism in the human fetal lung: implications for lung development and the pulmonary surfactant system.
It has been nearly 35 years since Liggins and Howie first reported the benefits of antenatal glucocorticoid (GC) treatment to promote the maturation of the human fetal lung, and nearly that long since Pasqualini and colleagues demonstrated that the human fetal lung actively metabolizes GCs. Since that time, our understanding of the effects of GCs on fetal lung maturation and pulmonary surfactant production has increased dramatically. Similarly, characterization of the enzymes involved in GC metabolism has greatly expanded our understanding of GC signaling in target tissues. In man, the biologically active GC (cortisol) and the biologically inactive GC (cortisone) are interconverted by the tissue-specific expression of the type 1 and type 2 11beta-hydroxysteroid dehydrogenase enzymes (HSD1 and HSD2). Much of the research on GC metabolism in peripheral target tissues has focused on the role of HSD1 in amplifying the effects of GCs in liver and adipose tissue or on the role of HSD2 in blocking the effects of GCs in the kidney and placenta. In contrast, the role of GC metabolism in modulating the effects of GCs on fetal lung maturation and the pulmonary surfactant system in humans is less understood. The goal of this review article is to present a brief overview of the role of GCs in human fetal lung maturation and pulmonary surfactant production, and to familiarize the reader with the biochemistry of the metabolism of natural and synthetic GCs by the HSD enzymes. In addition, we will review data concerning the expression and activity of the HSD enzymes in the human fetal lung and contrast this to what is known about the HSD enzymes in the fetal rodent lung. Although rodents, rabbits, sheep, and several primates have been invaluable model systems for the study of fetal lung development, we have chosen to largely focus this review on human lung, since there are significant differences in GC metabolism between humans and other species.
Garbrecht
Mark R
MR
Department of Anatomy and Cell Biology, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, 52242, USA.
Klein
Jonathan M
JM
Schmidt
Thomas J
TJ
Snyder
Jeanne M
JM
D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000378:metabolism; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000378:metabolism; D000818:Animals; D005260:Female; D005325:Fetal Organ Maturity / Q000187:drug effects / Q000502:physiology*; D005938:Glucocorticoids / Q000378:metabolism* / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology* / Q000378:metabolism*; D008171:Lung Diseases / Q000517:prevention & control; D011247:Pregnancy; D037661:Pulmonary Surfactant-Associated Proteins / Q000096:biosynthesis; D011663:Pulmonary Surfactants / Q000378:metabolism*
D005938:Glucocorticoids; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2